
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5772798/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Protective and therapeutic role for αB-crystallin in autoimmune demyelination. Nature, 2007, 448, 474-479.	27.8	458
2	pRESTO: a toolkit for processing high-throughput sequencing raw reads of lymphocyte receptor repertoires. Bioinformatics, 2014, 30, 1930-1932.	4.1	417
3	B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes. Science Translational Medicine, 2014, 6, 248ra107.	12.4	394
4	Comprehensive serological profiling of human populations using a synthetic human virome. Science, 2015, 348, aaa0698.	12.6	364
5	Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nature Medicine, 2007, 13, 211-217.	30.7	342
6	MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e89.	6.0	322
7	Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12468-12473.	7.1	265
8	Epstein–Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain, 2009, 132, 3318-3328.	7.6	243
9	Dysregulated T cell expression of TIM3 in multiple sclerosis. Journal of Experimental Medicine, 2006, 203, 1413-1418.	8.5	206
10	Models of Somatic Hypermutation Targeting and Substitution Based on Synonymous Mutations from High-Throughput Immunoglobulin Sequencing Data. Frontiers in Immunology, 2013, 4, 358.	4.8	197
11	Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis. Brain, 2011, 134, 534-541.	7.6	186
12	Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple Sclerosis. Journal of Immunology, 2009, 183, 4067-4076.	0.8	182
13	The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study. Brain, Behavior, and Immunity, 2013, 33, 131-138.	4.1	180
14	Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Annals of Neurology, 2009, 65, 639-649.	5.3	176
15	The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. Journal of Clinical Immunology, 2001, 21, 81-92.	3.8	155
16	Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein. Journal of Immunology, 2005, 175, 1974-1982.	0.8	155
17	B lymphocytes in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e104.	6.0	132
18	Specific peripheral B cell tolerance defects in patients with multiple sclerosis. Journal of Clinical Investigation, 2013, 123, 2737-2741.	8.2	130

#	Article	IF	CITATIONS
19	A Local Antigen-Driven Humoral Response Is Present in the Inflammatory Myopathies. Journal of Immunology, 2007, 178, 547-556.	0.8	121
20	Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. Journal of Neuroimmunology, 2011, 233, 245-248.	2.3	119
21	Autoantibodies frequently detected in patients with aplastic anemia. Blood, 2003, 102, 4567-4575.	1.4	105
22	Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. Journal of Neuroimmunology, 2003, 136, 140-148.	2.3	92
23	Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. Journal of Immunology, 2017, 198, 1460-1473.	0.8	92
24	B cells in the pathophysiology of myasthenia gravis. Muscle and Nerve, 2018, 57, 172-184.	2.2	87
25	Impaired Bâ€cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunological Reviews, 2019, 292, 90-101.	6.0	86
26	Interleukin-10+ Regulatory B Cells Arise Within Antigen-Experienced CD40+ B Cells to Maintain Tolerance to Islet Autoantigens. Diabetes, 2015, 64, 158-171.	0.6	80
27	Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis. JAMA Neurology, 2017, 74, 60.	9.0	80
28	11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1081-1092.	6.4	77
29	Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight, 2017, 2, .	5.0	71
30	Identification of Subject-Specific Immunoglobulin Alleles From Expressed Repertoire Sequencing Data. Frontiers in Immunology, 2019, 10, 129.	4.8	67
31	Autoreactive T Cells from Patients with Myasthenia Gravis Are Characterized by Elevated IL-17, IFN-γ, and GM-CSF and Diminished IL-10 Production. Journal of Immunology, 2016, 196, 2075-2084.	0.8	66
32	A Model of Somatic Hypermutation Targeting in Mice Based on High-Throughput Ig Sequencing Data. Journal of Immunology, 2016, 197, 3566-3574.	0.8	63
33	Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain, 2019, 142, 1598-1615.	7.6	62
34	The Microenvironment of Germ Cell Tumors Harbors a Prominent Antigen-Driven Humoral Response. Journal of Immunology, 2009, 182, 3310-3317.	0.8	59
35	Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Frontiers in Immunology, 2020, 11, 776.	4.8	59
36	Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1407-1409.	1.9	56

#	Article	IF	CITATIONS
37	Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology, 2022, 98, .	1.1	51
38	The B cell immunobiology that underlies CNS autoantibody-mediated diseases. Nature Reviews Neurology, 2020, 16, 481-492.	10.1	47
39	Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing– remitting multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1726-1733.	3.0	46
40	Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS. Journal of Neuroimmunology, 2007, 186, 164-176.	2.3	45
41	Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients. JCI Insight, 2019, 4, .	5.0	43
42	Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgDâ^'CD27â^' Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients. Journal of Immunology, 2019, 203, 1650-1664.	0.8	42
43	Compromised fidelity of Bâ€cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Annals of Clinical and Translational Neurology, 2016, 3, 443-454.	3.7	39
44	Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins. Frontiers in Immunology, 2015, 6, 600.	4.8	37
45	Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight, 2020, 5, .	5.0	37
46	Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1412, 154-165.	3.8	34
47	Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30649-30660.	7.1	33
48	Elevated Intrathecal Myelin Oligodendrocyte Glycoprotein Antibodies in Multiple Sclerosis. Archives of Neurology, 2010, 67, 1102-8.	4.5	32
49	CD4+ follicular regulatory T cells optimize the influenza virus–specific B cell response. Journal of Experimental Medicine, 2021, 218, .	8.5	30
50	COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	28
51	Demographic and clinical features of inclusion body myositis in north America. Muscle and Nerve, 2015, 52, 527-533.	2.2	27
52	Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry – The EXPLORE-MG registry. Journal of the Neurological Sciences, 2020, 414, 116830.	0.6	23
53	Autoantibodies Produced at the Site of Tissue Damage Provide Evidence of Humoral Autoimmunity in Inclusion Body Myositis. PLoS ONE, 2012, 7, e46709.	2.5	23
54	Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity. Journal of Immunology, 2019, 202, 2210-2219.	0.8	22

#	Article	IF	CITATIONS
55	Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	21
56	High-throughput investigation of molecular and cellular biomarkers in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	20
57	Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis. Journal of Experimental Medicine, 2020, 217, .	8.5	19
58	Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers. Disease Markers, 2006, 22, 213-225.	1.3	18
59	Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine, 2019, 42, 76-85.	6.1	18
60	Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. New England Journal of Medicine, 2016, 374, 1495-1496.	27.0	17
61	Cortical injury in multiple sclerosis; the role of the immune system. BMC Neurology, 2011, 11, 152.	1.8	15
62	A molecular view of multiple sclerosis and experimental autoimmune encephalitis: What can we learn from the epitope data?. Journal of Neuroimmunology, 2014, 267, 73-85.	2.3	14
63	Elevated N-Linked Glycosylation of IgG V Regions in Myasthenia Gravis Disease Subtypes. Journal of Immunology, 2021, 207, 2005-2014.	0.8	14
64	The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal of Neuroimmunology, 2022, 367, 577850.	2.3	9
65	Acute Demyelinating Disease after Oral Therapy with Herbal Extracts. Case Reports in Neurology, 2011, 3, 141-146.	0.7	4
66	Current and future immunotherapy targets in autoimmune neurology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 511-536.	1.8	4
67	Myasthenia gravis complement activity is independent of autoantibody titer and disease severity. PLoS ONE, 2022, 17, e0264489.	2.5	3
68	Brain tumor T cells inhibited by their natural KLR(B1) instinct. Science Immunology, 2021, 6, .	11.9	0
69	Lost in post-translational modification—Dengue virus writes its own sequel. Science Immunology, 2021, 6, .	11.9	0
70	B cells drive auto-T cells to the brain. Science Immunology, 2018, 3, .	11.9	0
71	Belly-born B cells bathe the brain. Science Immunology, 2019, 4, .	11.9	Ο
72	Sweet and low—autoantibodies deny oligodendrocytes their sugar fix. Science Immunology, 2020, 5, .	11.9	0

#	Article	IF	CITATIONS
73	Two mAbs take a stab at influenza's NActive site. Science Immunology, 2020, 5, .	11.9	0
74	GABA-cadabra: autoantibodies trick neurotransmitter receptors and induce seizures. Science Immunology, 2021, 6, eabn3790.	11.9	0
75	Reliability of patient self-reports to clinician-assigned functional scores of inclusion body myositis. Journal of the Neurological Sciences, 2022, 436, 120228.	0.6	0